Respiratory syncytial virus vaccine enters clinical testing

NIH-led trial to evaluate RSV vaccine’s safety in healthy adults.

A Phase 1 clinical trial to test the safety and tolerability of an investigational vaccine against respiratory syncytial virus (RSV) has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial also will assess the vaccine’s ability to prompt an immune response in healthy adult participants. The investigational vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH.

Read more View All News

This page was last updated on Friday, January 21, 2022